RSV in transplant and immunocompromised patients

Christine E Koval; Blanca E Gonzalez

doi:10.3949/ccjm.91.s1.06

RSV in transplant and immunocompromised patients

Cleve Clin J Med. 2024 Sep 4;91(9 suppl 1):S34-S41. doi: 10.3949/ccjm.91.s1.06.

Authors

Christine E Koval¹, Blanca E Gonzalez²

Affiliations

¹ Section Head, Transplant Infectious Diseases, Department of Infectious Diseases, Cleveland Clinic, Cleveland, OH; Associate Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.
² Center for Pediatric Infectious Diseases, Cleveland Clinic Children's Hospital, Cleveland, OH; Associate Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH gonzalb3@ccf.org.

PMID: 39231600
DOI: 10.3949/ccjm.91.s1.06

Abstract

Respiratory syncytial virus (RSV) is a significant cause of morbidity and mortality in infants, older adults, and patients with weakened immune systems. Disease severity differs by underlying immunologic pathologies, with worse outcomes associated with progression from upper to lower respiratory disease. In this review we address the impact of RSV in immunocompromised populations, and discuss the limited available treatments and the potential impact of newer RSV prevention strategies on immunocompromised adults and children.

Publication types

Review

MeSH terms

Adult
Antiviral Agents / therapeutic use
Child
Humans
Immunocompromised Host*
Infant
Respiratory Syncytial Virus Infections* / immunology
Respiratory Syncytial Virus Infections* / prevention & control

Substances

Antiviral Agents